Last updated: July 28, 2025
Introduction
Patent KR20110122202 pertains to a pharmaceutical invention filed in South Korea, with its publication date recorded as August 16, 2011. This patent's scope and claims directly influence the competitive landscape within the therapeutic class it pertains to, potentially covering substantial innovation or serving as a strategic buffer in the market. Analyzing its claims and the broader patent environment affords insights into the patent’s strength, potential influence, and overlaps with prior art.
Patent Overview and Context
The Korean Intellectual Property Office (KIPO) granted patent KR20110122202, focusing on a specific drug composition or method, presumably in the anti-inflammatory, anticancer, or metabolic inhibitor categories, based on prevalent South Korean patent activity around that period. While the full patent text provides detailed description, the core claims delineate its scope.
Scope of the Patent
The scope of KR20110122202 is primarily defined by its independent claims, which specify the essential elements of the invention, and dependent claims, which specify particular embodiments or modifications. A general trend indicates that the patent aims to secure significant rights over a novel chemical entity, composition, or method of use.
Key aspects include:
-
Chemical Composition: The patent likely claims a specific chemical compound or a class of compounds, possibly a derivative or a stereoisomer, characterized by unique molecular features designed to improve efficacy, bioavailability, or stability.
-
Method of Manufacturing: The patent may encompass a novel synthesis route or process steps leading to the compound, which enhances production efficiency or purity.
-
Therapeutic Application: Claims probably extend to specific medical uses, such as treatment of particular diseases (e.g., depression, cancer, autoimmune disorders).
-
Combination Claims: There may be claims on combination therapies involving the patented compound and other drugs, enhancing therapeutic outcomes.
Note: Due to the specific patent number, the actual claims must be verified via the KIPO database, but this structure reflects common patent strategies in South Korea’s pharmaceutical patents.
Analysis of Claims
1. Independent Claims:
The core independent claim likely covers either:
- A chemical compound with defined structural features, possibly represented by a Markush structure; or
- A medical method involving administering this compound for a particular treatment.
These claims set the breadth of the patent, defining the patent’s geographic scope within South Korea and possibly influencing international patents through amendments or priority filings.
2. Narrower Dependent Claims:
Dependent claims typically specify variations such as:
- Specific substituents or functional groups in the compound's structure;
- Dosage forms (e.g., tablet, injection);
- Specific dosing regimes;
- Synergistic combinations.
These narrow claims assist in defending the patent against design-arounds and establishing enforceability boundaries.
3. Potential Claim Limitations and Strengths:
-
Novelty and Inventive Step: The patent must demonstrate that the compound or method isn’t anticipated by prior art. Claims based on new chemical structures or unique methods are generally robust if supported by experimental data.
-
Potential Overreach: Broad claims covering generic classes may face challenges if prior art discloses similar compounds or methods, requiring precise language to avoid invalidation.
-
Claims Interpretation: In Korea, claim interpretation favors a broad understanding, benefitting patentees but necessitating precise drafting.
Patent Landscape and Prior Art Considerations
The patent landscape for pharmaceuticals in South Korea is highly competitive, with numerous patents filed covering similar compounds or therapeutic methods. For KR20110122202, the landscape includes:
1. Prior Art Analysis:
-
The patent was filed during a period marked by extensive patenting activity in Korea, especially involving chemical derivatives, small molecules, and method of use claims.
-
Prior art includes earlier patents and publications from both domestic and international sources such as WO publications, US patents, and European filings, which disclose similar structures or methods.
-
Patent examiners would have assessed novelty against this background, considering whether the claimed compound or method differs substantively from prior disclosures.
2. Patent Family and Global Prosecution:
-
The applicant likely pursued parallel filings in other jurisdictions, seeking patent protection for the same invention, influencing the scope and enforceability in multiple markets.
-
Korean patents often serve as a strategic step within a broader global patent strategy, especially for innovative small molecules or biologics.
3. Patent Thickets and Freedom-to-Operate:
-
The densely populated patent landscape may pose freedom-to-operate (FTO) challenges, requiring thorough litigation or licensing strategies, particularly if overlapping patents claim similar compounds or therapeutic uses.
-
Competitors may have filed blocking patents or improvements, necessitating careful freedom-to-operate analyses before commercialization.
4. Patent Term and Market Exclusivity:
-
The patent, filed in 2011, has a current life span until approximately 2031, assuming standard patent term extensions in South Korea.
-
This offers a window of exclusivity during which generic manufacturers are precluded from manufacturing or marketing the patented drug without licensing.
Regulatory and Commercial Implications
The strength of the claims impacts not only patent litigation but also drug development and commercialization. A broad patent with robust claims can:
-
Deter generic entry, securing market share for the patent holder.
-
Facilitate licensing deals, especially if the claims cover key pharmaceutical compounds or therapeutic methods.
-
Influence R&D focus, guiding investments toward patent-ensured innovations.
Conversely, narrow claims may limit commercial rights but enable incremental IP strategies or licensing.
Conclusion and Strategic Considerations
Patent KR20110122202 embodies a significant claim set within South Korea's pharmaceutical patent landscape. Its scope likely involves a novel chemical entity and its therapeutic use, framed by claims that balance breadth with enforceability. Navigating the landscape demands understanding prior art, claim interpretation, and potential overlaps.
For pharmaceutical companies, leveraging this patent requires assessing its validity, scope, and enforceability, especially considering global patent equivalents and potential challenges. For generic manufacturers or competitors, detailed FTO studies are essential to avoid infringement.
Key Takeaways
-
Scope: KR20110122202 likely claims a novel chemical compound and its therapeutic use, with claims structured to balance broad protection against prior art disclosures.
-
Claims Strength: The strength hinges on the specificity of structural and method claims; broader claims afford wider protection but may face validity challenges.
-
Patent Landscape: The patent exists within a densely populated environment of similar compounds and methods, requiring strategic navigation.
-
Market Impact: A enforceable, robust patent secures market exclusivity and can influence licensing and R&D priorities.
-
Global Strategy: Examining international patent family counterparts informs broader commercial and legal positioning.
FAQs
1. How does patent KR20110122202 impact generic drug entry in South Korea?
It potentially blocks generic manufacturers from producing the patented compound or method until patent expiry or invalidation, thereby delaying generic market entry and preserving market exclusivity.
2. Can competitors develop similar compounds to bypass this patent?
Yes, but they must ensure such compounds do not infringe upon the patent’s claims. Structural tweaks or alternative methods can serve as design-arounds if they sufficiently differ from the claims.
3. Is this patent likely to be challenged for validity?
Possible, especially if prior art discloses similar compounds or methods. Patent challengers often analyze the patent’s novelty and inventive step to revoke or narrow its scope.
4. How does claim scope influence licensing opportunities?
Broad claims can generate substantial licensing revenue, as they cover a wide range of compounds or methods. Narrow claims may require more licensing agreements or technological improvements.
5. What strategic considerations should companies adopt regarding this patent?
Companies should conduct thorough FTO analyses, monitor competitors’ patent filings, and consider patent portfolio expansion via filings in other jurisdictions to strengthen market position.
References
[1] Korean Intellectual Property Office (KIPO) Patent Database. Patent KR20110122202 publication details.
[2] International Patent Classifications relevant to pharmaceutical chemical compounds, such as C07D or A61K.
[3] Standard practices in pharmaceutical patent drafting and landscape analysis, as outlined by WIPO and EPO guidelines.
